CD274 and non-small cell lung carcinoma: These data on the ALI index, already known since 2013 for its prognostic role in lung cancer patients treated with chemotherapy [25], are in line with those reported by a recent retrospective study including 672 patients with stage IV NSCLC treated with PD-L1 inhibitors alone or in combination with chemotherapy.